Sarepta Therapeutics (SRPT) EBT Margin (2010 - 2026)
Sarepta Therapeutics' (SRPT) quarterly EBT Margin came in at 46.96% in Q1 2026, up 33460.0% year-on-year from N/an in Q1 2025, and up 174.74% quarter-over-quarter from 62.83% in Q4 2025.
Sarepta Therapeutics (SRPT) EBT Margin (2010 - 2026) Analysis & Trends
Sarepta Therapeutics' EBT Margin history runs 15 years deep, the most recent figure standing at 46.96% for Q1 2026.
- On a quarterly basis, EBT Margin rose 33460.0% year-over-year to 46.96% in Q1 2026; TTM through Mar 2026 was 1.12%, a 1124.0% increase from a year earlier, with the FY2025 full-year figure at 37.67%, down 5138.0% from the prior year.
- EBT Margin advanced to 46.96% in Q1 2026 per SRPT's latest filing, from 62.83% in the prior quarter.
- Across five years, EBT Margin topped out at 46.96% in Q1 2026 and bottomed at 287.64% in Q1 2025.
- The 5-year median for EBT Margin is 5.58% (2023), against an average of 44.08%.
- Across the five-year window, EBT Margin tumbled 29766 bps in 2025 and soared 33460 bps in 2026, its largest moves.
- Year by year, EBT Margin stood at 38.93% in 2022, then tumbled by 90 bps to 3.74% in 2023, then jumped by 597 bps to 26.08% in 2024, then plunged by 341 bps to 62.83% in 2025, then soared by 175 bps to 46.96% in 2026.
- Per Business Quant, the three latest SRPT EBT Margin figures stand at 46.96% (Q1 2026), 62.83% (Q4 2025), and 48.59% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 17.13% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 33.74% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Sarepta Therapeutics | 1.66 Bn | 1.25 Bn | 622.04 Mn | 46.96% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 46.96% |
| Dec 31, 2025 | -62.83% |
| Sep 30, 2025 | -48.59% |
| Jun 30, 2025 | 25.14% |
| Mar 31, 2025 | -287.64% |
| Dec 31, 2024 | 26.08% |
| Sep 30, 2024 | 7.28% |
| Jun 30, 2024 | 3.74% |
| Mar 31, 2024 | 10.02% |
| Dec 31, 2023 | 3.74% |
| Sep 30, 2023 | -10.72% |
| Jun 30, 2023 | -5.58% |
| Mar 31, 2023 | -221.48% |
| Dec 31, 2022 | 38.93% |
| Sep 30, 2022 | -111.36% |
| Jun 30, 2022 | -107.98% |
| Mar 31, 2022 | -55.16% |
| Dec 31, 2021 | -68.20% |
| Sep 30, 2021 | -212.97% |
| Jun 30, 2021 | -49.83% |